Published in Drug Week, May 2nd, 2003
The Niferex product line includes Niferex Tablets, Niferex 150 Capsules, and Niferex 150 Forte. The transaction, valued at approximately $14.3 million and including applicable intellectual property for each of the products, will position KV to build a leading position in this oral hematinic market.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.